Study S001446

A Randomized, Double-blind, Placebo-controlled Study the Efficacy and Safety of Supaglutide in Chinese Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03745885
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 48
Start: 2018-12-04
Primary completion: 2019-06-10
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Supaglutide injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Pharmacokinetic：Cmax of Supaglutide [baseline and up to 29 days after formal dose]
Pharmacokinetic: Tmax of Supaglutide [baseline and up to 29 days after formal dose]
Pharmacokinetic: AUC0-t of Supaglutide [baseline and up to 29 days after formal dose]
Pharmacokinetic: t½ of Supaglutide [baseline and up to 29 days after formal dose]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006753	Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes. Lou YR, Clinical pharmacokinetics	2025	Other trial	PMID 39961992 DOI	cites ClinicalTrials.gov:NCT03745885; registry reference DERIVED:39961992